| Tyzeka (telbivudine) / Novartis |
NCT01260610: Randomized Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug in HBeAg Negative Chronic Hepatitis B Patients |
|
|
| Withdrawn | N/A | 0 | RoW | Tenofovir, Telbivudine, Tenofovir plus Telbivudine | Institute of Liver and Biliary Sciences, India | Chronic Hepatitis B | 06/11 | 06/11 | | |
NCT01958229: Efficacy Study of Telbivudine in Chronic Hepatitis B Patients |
|
|
| Completed | N/A | 23 | RoW | | National Taiwan University Hospital | Chronic Hepatitis B, Roadmap Concept in Chronic Hepatitis B Treatment, 24-week PCR Negativity of Telbivudine, PCR Negativity at 52 and 104 Week, HBeAg Seroconversion Rate at 52 and 104 Week | 03/12 | 04/13 | | |
NCT01732224: To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B |
|
|
| Completed | N/A | 69 | RoW | Tenofovir + Telbivudine, Tenofovir | Institute of Liver and Biliary Sciences, India | Spontaneous Reactivation of Hepatitis B | 04/14 | 04/14 | | |
NCT02049736: Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal Diseases |
|
|
| Withdrawn | N/A | 0 | RoW | Telbivudine | Chinese University of Hong Kong | Chronic Hepatitis B | 06/15 | 06/15 | | |
